The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …

Answer questions and earn CME/CNE Advances in genomics and molecular biology have
identified aberrant proteins in cancer cells that are attractive targets for cancer therapy …

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an
important part of standard therapy in multiple cancer indications. With expanded clinical …

Chemotherapy-induced hand-foot syndrome and nail changes are common complications of
many classic chemotherapeutic agents and the newer molecular targeted therapies. They …

Sorafenib is the first multi‐kinase inhibitor (TKI) approved for the treatment of advanced
hepatocellular cancer (HCC) and metastatic renal cell cancer (RCC) and is increasingly …

Background Regorafenib is an orally available, small-molecule multikinase inhibitor with
international marketing authorizations for use in colorectal cancer and gastrointestinal …

The hand‐foot‐syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy‐
associated acral erythema) is characterized by painful predominantly palmo‐plantar lesions …

Tyrosine kinase inhibitors have been successfully developed in combination with immune
checkpoint inhibitors to treat advanced renal cell carcinoma (RCC), further advancing …

Background A retrospective, registry-based analysis to assess the outcomes of metastatic
renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed …

Abstract Purpose: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor
(FGF), VEGF, and platelet-derived growth factor receptors. This phase I/II dose–escalation …